Biovica International announced that the company has received a PLA code from the AMA (American Medical Association), an important milestone in the commercialization of DiviTum® TKa in the United States. The PLA code is a specific code for the DiviTum® TKa test issued by the AMA and enables payers and providers to readily identify service and reduce administrative burden for providers and payers. Effective October 1, 2023, the code will be used for billing, reporting, and processing healthcare claims.